Brief: Pharming Group Announces Positive Phase II Topline Data For Leniolisib In Pids With Immune Dysregulation
22/09/2026 06:02
BRIEF-Pharming Group Announces Positive Phase II Topline Data For Leniolisib In Pids With Immune Dysregulation Sept 22 (Reuters) - Pharming Group N.V. PHAR.AS:
ANNOUNCES POSITIVE PHASE II TOPLINE DATA FOR LENIOLISIB IN PIDS WITH IMMUNE DYSREGULATION ACCEPTED AS LATE-BREAKING ABSTRACT AT ESID 2026
EXPECTS TO REPORT TOPLINE RESULTS FROM A PHASE II TRIAL OF LENIOLISIB IN CVID IN Q4 2026
Source text: ID:nGNE8vpmwW
Further company coverage: PHAR.AS
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com ; +48 58 769 66 00;;))